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Gloria Crispino, PhD‡; Edmund C. Lalor, PhD§; Brendan J. Conlon, MD†¶
Objectives: Tinnitus is the perception of sound in the absence of an external auditory stimulus. It is widely believed that tinnitus,
in patients with associated hearing loss, is a neurological phenomenon primarily affecting the central auditory structures. How-
ever, there is growing evidence for the involvement of the somatosensory system in this form of tinnitus. For this reason it has
been suggested that the condition may be amenable to bi-modal stimulation of the auditory and somatosensory systems. We
conducted a pilot study to investigate the feasibility and safety of a device that delivers simultaneous auditory and somatosensory
stimulation to treat the symptoms of chronic tinnitus.
Methods: A cohort of 54 patients used the stimulation device for 10 weeks. Auditory stimulation was delivered via headphones
and somatosensory stimulation was delivered via electrical stimulation of the tongue. Patient usage, logged by the device, was
used to classify patients as compliant or noncompliant. Safety was assessed by reported adverse events and changes in tinnitus
outcome measures. Response to treatment was assessed using tinnitus outcome measures: Minimum Masking Level (MML), Tinni-
tus Loudness Matching (TLM), and Tinnitus Handicap Inventory (THI).
Results: The device was well tolerated by patients and no adverse events or serious difficulties using the device were reported.
Overall, 68% of patients met the defined compliance threshold. Compliant patients (N5 30) demonstrated statistically significant
improvements in mean outcome measures after 10 weeks of treatment: THI (211.7 pts, p< 0.001), TLM (27.5dB, p< 0.001), and
MML (29.7dB, p< 0.001). The noncompliant group (N5 14) demonstrated no statistical improvements.
Conclusion: This study demonstrates the feasibility and safety of a new bi-modal stimulation device and supports the potential
efficacy of this new treatment for tinnitus.
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INTRODUCTION
Tinnitus is the perception of sound in the absence of an external,
auditory stimulus and is commonly described as “ringing in the ears”
(1–3). The condition is heterogeneous with a diverse range of etiolo-
gies (4) but it is commonly accompanied by a sensorineural hearing-
loss (SNHL) (5). Tinnitus, as a result of SNHL, is widely believed to be
a neurological phenomenon (6). Increased bursting and synchronic-
ity in central auditory structures, as a result of cochlear pathology,
have been implicated in the generation of tinnitus (7). A prevailing
theory is that tinnitus is a reaction to reduced information in the fre-
quency bands damaged by hearing loss. This has led researchers to
investigate methods of acoustically stimulating the damaged fre-
quency bands as a means of alleviating symptoms.
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Studies have found that specifically designed auditory stimuli
may reverse neural pathologies (8,9). These findings support the
theory that programmable hearing aids, if suitably tuned, could
compensate for frequency-dependent deficits and thus alleviate the
symptoms of the resulting tinnitus (10,11). Additionally, tinnitus sup-
pression has been observed in cases of cochlear implants (12), which
use an electrode array to directly stimulate the auditory nerve. Yet,
the clinical evidence to support the longer-term benefit of hearing
aids (13) or cochlear implants is limited. The use of other sensory
channels may represent an additional option to compensate for the
shortcomings of auditory interventions.
Animal studies indicate the involvement of the somatosensory
system in the generation of tinnitus (14). It has been observed that
pairing auditory and somatosensory stimulation can influence the
response characteristics of auditory cortical, collicular and brainstem
neurons in noise-damaged guinea pigs (15). This represents a poten-
tial approach for suppressing the neural activity hypothesized to be
associated with tinnitus (16,17). Combining auditory stimulation
with invasive nucleus basalis and vagus nerve stimulation (VNS) has
been shown to promote neuroplasticity and modulate the response
characteristics of auditory cortical neurons in rats (18). Koehler and
Shore (19) found similar effects in auditory brainstem neurons by
combining auditory stimulation with somatosensory stimulation.
Combining auditory and transcutaneous VNS (tVNS) stimulation has
been shown to promote similar effects in humans (20).
Bi-modal stimulation is emerging as a compelling approach to tin-
nitus treatment (21–24). De Ridder et al. (25) paired tones with VNS
in 10 tinnitus patients who were previously unresponsive to other
treatments. The study found that patients on certain medications
did not respond to the treatment. After adjusting for this finding,
the mean reduction in Minimum Masking Level (MML) and Tinnitus
Handicap Inventory (THI) scores from baseline was 18.8 dB and 28%
respectively. Another study of tVNS and auditory stimulation found
that 18% of participants responded to the treatment. Responders in
this study had a 43% reduction on the Visual Analogue Scale (VAS)
loudness score (26). A recent study of 30 patients reported encour-
aging results for tVNS paired with notched music in some tinnitus
outcomes measures (VAS loudness and VAS awareness) but not in
others (THI) (27).
In this paper, we present the results of an open-label, single-
arm, pilot study to investigate the feasibility and safety of an inno-
vative form of combined auditory and somatosensory stimulation.
The intervention delivers sound paired with electrical stimulation
of the trigeminal nerve via the tongue. This pilot study forms the
beginning of a stepped approach to investigating the efficacy of
this intervention and will be followed by parameter optimization
and randomized control trials, the recommended approach
to evaluating new therapeutic interventions for their feasibility,
safety, and efficacy (28).
MATERIALS AND METHODS
Multimodal Stimulation
A combined auditory-somatosensory stimulator was employed in
this study (mutebutton@TM model MB2011, Neuromod Devices Ltd.,
Dublin, Ireland). This device can be programmed to simultaneously
deliver auditory stimulation through hi-fidelity headphones and
transcutaneous electrical stimulation of the trigeminal nerve through
an array of 32 electrical stimulators on the antero-dorsal surface of
the tongue. The anterior aspect of the dorsal surface is the most
densely innervated part of the tongue offering extensive somatosen-
sory bandwidth for a relatively small stimulator surface area. In
addition, the tongue has a persistent electrolytic fluid (saliva) that
enhances electrical conductivity between electrodes and the tongue.
Somatosensory stimulation was delivered in the form of bi-phasic
anodic pulses of 17.5 ms duration and variable amplitude. The high-
fidelity headphones were capable of delivering CD quality audio (20
Hz to 20 kHz, 23 dB, 16-bit stereo) with amplitude variable more
than a 75 dB range (from 5 dBA to 80 dBA SPL).
The auditory stimulus was spectrally broad (wideband noise) and
contained a high rate of temporal events (recording of rainfall)
mixed with classical music (recordings of piano works by Erik Satie).
The wideband sound stimulates a broad spectrum of auditory path-
ways while the music provides a focal point in the soundscape to
aid the user maintain attention (29). The auditory stimulus was spec-
trally modified to compensate for the deficit in the patient’s hearing
profile. A band-boost filter with center frequency correlating to the
fall-off frequency, as determined by the patient’s audiogram, was
applied. Boosting the frequency components of the auditory stimu-
lus in this way stimulates the affected hearing bands most com-
monly associated with SNHL related tinnitus.
The somatosensory stimulus was derived by temporal-spectral
transformation of the auditory stimulus with a tonotopic mapping.
The 4-octave range was divided so that all critical bands were cov-
ered (maximum six critical bands in an octave within this range)
each octave was assigned eight frequency bins. The stimulator was
programmed to map each of these frequency bins to a unique elec-
trode. The auditory and somatosensory stimuli were synchronized,
with no more than6 1 ms delay between.
Both stimulation intensities were adjustable by the patient,
according to individual comfort levels. The range for the auditory
stimulus was from 5 to 80 dBA and was adjustable via a rotary dial
with discrete steps of 1.5 dBA. The somatosensory intensity was
adjustable via a rotary dial whereby the patient could set the inten-
sity to one of 17 discrete levels. A study by Tyler et al. (30), which
administered electro-tactile stimulation of the tongue to address
vestibular dysfunction employed a training regime of between 30
and 60 minutes per day. The recommended session duration in this
study was set to a minimum of 30 minutes per day for a period of
10 weeks.
Tinnitus Severity Measures
Several outcome measures were sampled throughout the study.
These were assessed in the clinical environment at the enrolment
visit and every two weeks at “review” visits. The instrument chosen
to assess the subjective outcome was the THI. The THI is a 25-item
self-reporting questionnaire for the measurement of tinnitus (31).
The instruments employed to assess psychoacoustic outcomes were
the Tinnitus Loudness Matching (TLM) (32), and (MML) (33). These
measures determine the intensity of the perceived tinnitus and low-
est level of noise required to mask the tinnitus. Both measures are
expressed in dB HL.
Subjects
Self-referred tinnitus patients that met inclusion/exclusion criteria
(see below) were recruited in the order in which they presented at
the clinic and not preselected in any way. Sixty-four patients were
screened for eligibility. Written informed consent was obtained from
54 patients with chronic tinnitus (19 female; mean5 45 years, range
28–64 years, 35 male; mean5 47 years, range 21–64 years). The exact
definition of chronic tinnitus varies in the literature, for the purposes
of this study chronic tinnitus is defined as tinnitus that has not
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self-resolved within six months. Constant tinnitus refers to tinnitus
that is present every day (34–36). The eligibility of study participants
was determined by the following inclusion and exclusion criteria:
Inclusion Criteria
• Aged between 18 and 65 years
• Suffering from constant, subjective tinnitus> six months
• Age or noise related sensorineural hearing loss (>25 dBHL in at
least one ear and at least one frequency up to and including 8 kHz).
Exclusion Criteria
• Ulceration of oral cavity or tongue, oral mucosa or significant
intra-oral disease
• Meniere’s Disease
• Current medical legal cases regarding tinnitus
• Currently undergoing any pharmacological or electrical stimulation-
based treatment for tinnitus
• Pacemakers
Study Design
This was a 14-week pilot study to assess the feasibility and safety
of a device that delivers a combination of auditory and somatosen-
sory stimulation and investigate the potential efficacy of this inter-
vention. Patients visited the clinic every two weeks for the duration
of the study. Patients were assessed without any intervention in a
clinical setting for the first three screening visits, the run-in phase, to
establish baseline outcome measures of tinnitus (pretreatment). The
patients were not required to perform any tasks in-between these
visits. In addition to the THI, TLM, and MML, tinnitus related informa-
tion such as the type of tinnitus, pure tone/narrowband, tinnitus
duration and the VAS loudness was collected, Table 1.
There are several nontreatment factors that can affect the per-
ceived benefit from any treatment of tinnitus. Hesser et al. (37)
reviewed the response rates of patients on a waitlist for tinnitus
treatments and found that distress can reduce over short wait peri-
ods. This improvement can be attributed to the attention and reas-
surance the patient expects to receive from the investigator and/or
knowledgeable professional, as well as anticipation of an improve-
ment from the study. The run-in phase of this study was employed
to address this anticipatory effect from study participation. Assess-
ment scores from the third screening visit were used as baseline val-
ues. It was expected that any improvement from the anticipatory
effect of study participation would be mitigated by the third visit.
At the third visit patients were provided with the stimulation device
to take home for the remainder of the study and asked to use it for
between 30 and 60 minutes every day for 10 weeks. Patients were
shown how to use the device and told to set the auditory and soma-
tosensory stimulation to the most comfortable levels for them.
Instructions for use included information on cleaning and storing the
device, i.e. sterilizing the tongue tip before initial use and storing the
device in a dry location without extreme temperatures. There were
no specific cleaning instructions to be completed during the study.
Patients were asked to return to the clinic every two weeks to repeat
the assessments carried out in the run-in phase. Where it was not pos-
sible for participants to return to the clinic, they completed the paper
version of the THI remotely and sent the copy to the investigator site
by post. These interim assessments were employed to monitor any
significant changes in tinnitus symptoms. Patients were advised to
terminate device use and to contact the investigator if they experi-
enced any side effects or adverse events. Patients were provided with
email and phone numbers and instructed to contact the research
team regarding any device malfunction or safety concerns.
A Clinical Audiologist under the clinical supervision of a Senior
Consultant Otolaryngologist Head & Neck Surgeon conducted the
study. The same audiologist performed all assessments. Assessment
scores were recorded in a paper-based system. While the audiologist
was not blinded from previous results, they did not refer to previous
assessment scores during evaluation.
Compliance Monitoring and Data Inclusion Criteria
Patient compliance was assessed using an embedded data log-
ging function on the device. This data was used to determine the
total number of completed sessions per day and the duration of
each session. The protocol required participants to use the device
for between 30 and 60 minutes per day, 7 days per week. The com-
pliance rate describes the proportion of protocol compliant sessions
achieved by patients over the course of 10 weeks.
In pharmaceuticals studies, patients are considered compliant if
their adherence is greater than 80% (38). Given the investigational
nature of this study a more generous compliance threshold was
employed, i.e. 66% or 46 sessions in 10 weeks. The cohort was divided
into compliant and noncompliant groups according to this threshold.
Analysis
Log data from the devices provided details on patient’s device
usage including auditory and somatosensory stimulation levels.
Analysis of this data was employed to provide insights into device
acceptability. The device was certified for electrical and biocompati-
bility safety prior to the study. Therefore study safety was assessed
through changes in tinnitus outcome measures and reported side
effects or adverse events.
The exploratory efficacy analysis investigated whether any statisti-
cal improvement in THI, TLM, or MML was observed after 10 weeks
of treatment. Patient’s data was included in the analysis if symptom
scores were available for Baseline (V2) and the penultimate or final
visit, and if they met the minimum compliance threshold.
Baseline THI scores were not normally distributed, so the Wil-
coxon signed rank test was employed to test for statistical signifi-
cance between Baseline (V2) and final values. TLM and MML
datasets were found to be normally distributed and a paired t-test
was employed to test for statistically significant differences between
Baseline (V2) and final values. The proportion of patients achieving
Table 1. Demographic Profile of Participants.
Included in analysis,
N5 54
Age 47.56 11
Men 34 (63%)
Tinnitus type: pure tonal/narrowband 31 (66%)/16 (34%)
Persistence of tinnitus: >2 years/<2 years 36 (78%)/10 (22%)
Tinnitus presence: one ear/both ears 12 (26%)/34 (74%)
Tinnitus severity, (VAS)* 6.56 2.2
Tinnitus Handicap Inventory 416 22.6
Minimum Masking Level (dB HL) 51.66 19.7
Tinnitus Loudness Matching (dB HL) 42.656 19.9
Hyperacusis: yes/no 13 (28%)/ 41 (72%)
Tinnitus type: constant/fluctuating/other 31 (57%)/15 (28%)/8 (15%)
Taking anti-depressant medications 5 (11%)
*Self-rated Visual Analogue Scale, scale 1–10.
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clinically significant improvements was also assessed. Clinical mean-
ingfulness was informed by the literature. Jastraboff et al. (39)
reported that a decrease in 5.3 dB on the MML scale significantly
correlated to patients reporting improvements in their tinnitus.
While Zeman et al. (40) demonstrated that a 7-point drop in THI
score also reflects a clinically significant improvement. Equivalent
analysis for TLM was not included as no values for the clinically sig-
nificant reduction for TLM could be found in the literature. Sub-
analysis was completed by comparing differences in symptom
scores between compliant and noncompliant groups.
Study Registration
The study was approved by the Research Ethics Committee (REC)
of the National University of Ireland, Maynooth. Nether the REC or
the Hermitage Medical Centre required registration to a clinical trials
registry. The study was considered a feasibility study, and was there-
fore exempted from registration under FDAAA 801.
RESULTS
Demographic Data
A cohort of 54 patients was recruited as part of this study; each
patient was required to complete three intervention free assess-
ments and five subsequent assessments while using the device. The
total duration of the study was 14 weeks.
Two patients dropped out of their own accord. Log data from the
devices of six additional patients showed very little use of the device
over the study period (< 10% compliance). Two additional patients
were excluded from analysis; while their corresponding log data
showed active use of the device, they did not return for any assess-
ment visits after the third assessment. In total ten patients were
excluded from the final analysis. Table 1 presents the demographic
data of the 54 participants enrolled in the study.
Feasibility and Safety
No adverse events or side effects, in terms of safety, comfort or
tolerability of the device, related or unrelated to tinnitus, were
reported over the course of this study. Two patients demonstrated
clinically significant increases in THI scores between Baseline (V2)
and final values; from 50 pts to 60 pts and 18 pts to 36 pts respec-
tively, but did not report a corresponding increase in tinnitus loud-
ness scores (MML or TLM). Two other patients demonstrated
clinically significant increases in MML scores between Baseline (V2)
and final values; from 60 dB to 68 dB and 38 dB to 52 dB, but did
not report increased psychological impact (THI). None of these
patients reported corresponding clinically significant increases in tin-
nitus loudness or psychological impact nor did they report the
changes as adverse events or side effects. Log data showed that
these patients were noncompliant to the protocol.
Three devices were reported as malfunctioning over the course of
the study. One was dropped and physically damaged by the patient
and the remaining two devices were reported as not delivering any
stimulation on the tongue. It was found that the patients had incor-
rectly followed the cleaning instructions and had compromised their
operation. These devices were replaced by courier within 24 hours.
At the end of the study the Technical Investigation Team checked
all returned devices and all device were found to be functioning
correctly.
Device Usage
Log data from the devices provided details on patient’s usage
including auditory and somatosensory stimulation levels. Data from
three patients was excluded from this analysis due to errors in the
electronic logging system on their devices. On the days the device
was used, the average session duration for all patients was 47 min
(N5 44, SD5 20 min). The average treatment duration across all
patients was 67 days. Table 2 presents the usage statistics of the
compliant and noncompliant groups.
The average somatosensory and auditory stimulation settings
after the first week of use were 6 pts (SD5 4.2) (min 0 and max
17) and 71.5 dBA (SD5 8.1 dBA) respectively. The average soma-
tosensory and auditory stimulation settings extracted from log
data for the final week were 7.4 pts (SD5 5.4) and 64 dBA
(SD5 6.6 dBA) respectively. There was no statistically significant
difference between the stimulation setting at the beginning and
end of treatment. Patients were able to modify the volume of the
audio and the intensity of the somatosensory stimulation over the
10 weeks of treatment. From the log data it was observed that
patients varied the somatosensory stimulation much more than
the auditory stimulation; the average coefficient of variation (COV)
for the full cohort was 35% and 15% for somatosensory and audi-
tory stimulation settings respectively. There was no significant
relationship observed between stimulation settings and changes
in outcome measures.
Efficacy
Efficacy of this intervention was determined by measuring
changes in THI, TLM and MML scores between baseline and final val-
ues. The symptom scores were assessed without intervention at the
three run-in phase visits, i.e. V0, V1, and V2, to better understand the
variability and improvements in symptoms that may be attributed
to noninterventional influences. Average THI, TLM, and MML scores
dropped by 7.8 pts (p< 0.001), 1 dB (p5 0.54), and 5.7 dB (p< 0.01)
between V0 and V2. The average intra-subject COV for the THI, TLM,
and MML scores over the three baseline visits were 21%, 16%, and
13% respectively. Baseline values for analysis were taken from the
third screening visit, i.e., Baseline(V2). The average and standard
deviation for Baseline(V2) and final values can be seen in Table 3.
The most significant improvement in symptom scores was observed
for the compliant group. The average values for THI, TLM, and MML
reduced by a further 11.7 pts (p< 0.001), 7.5 dB (p< 0.001), and 9.8
dB (p< 0.001) respectively, beyond the changes observed over the
run-in phase. No significant improvements were observed for the
noncompliant group. The average values for THI, TLM, and MML
reduced by 1.9 pts, 0.9 dB and, 4.7 dB respectively.
Table 4 presents the number of patients who achieved clinically
significant improvements, per outcome measure, for compliant and
noncompliant groups. The highest proportion of improvers are seen
Table 2. Average Usage Statistics for Compliant and Noncompliant
Groups.
Average number of
compliant days (SD)
Average session
duration, mins (SD)
Compliant (30)* 59 (12.3) 52 (18)
Noncompliant (14)† 33 (9.4) 33 (17)
*> 46 days with at least 1 daily session duration>30 min.
†< 46 days with at least 1 daily session duration>30 min.
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on the MML scale with 73% of the 30 compliant patients demon-
strating a clinically significant improvement in MML.
DISCUSSION
This open-label, pilot study assessed the feasibility, safety and ini-
tial efficacy of an innovative medical device for treating tinnitus. The
feasibility of deploying this device is supported by the compliance
data; 67% of patients achieved the minimum number of sessions
required over the study period. The remaining patients continued to
use the device sporadically for the duration of the study. The study
found no systematic safety issues, adverse events or side effects
from use of the device. These findings suggest that noncompliance
was due to disengagement with the treatment rather than difficulty
using the device. More research is required to understand the bal-
ance between minimally acceptable session duration and the mini-
mum session duration required for efficacy of the treatment.
The protocol allowed patients to modify the stimulation settings
to allow for individual comfort levels. This resulted in significant vari-
ability in the dataset and no relationships between stimulation set-
tings and changes in tinnitus symptoms were observed. However,
there is evidence in the literature that stimulation settings can
impact the efficacy of tinnitus treatments (42,43). This will be further
investigated in future studies.
Compliance appears to be a significant factor in achieving
improvement in tinnitus symptoms with this treatment. The compli-
ant group (N5 30) were found to have achieved significant
improvement in all outcome measures; average THI was reduced by
11.7 pts (34% relative decrease), average TLM by 7.5 dB and MML by
9.7 dB, Table 3. These values are not only statistically significant but
57% and 73% of the compliant patients achieved clinically signifi-
cant improvements for THI and MML respectively. The noncompliant
group (N5 14) achieved an average 1.9 pt (6% relative decrease),
0.9 dB and 4.9 dB reduction in THI, TLM, and MML respectively. This
relationship between compliance and improvement requires further
investigation as this finding may be associated with a selection
effect as opposed to a dose effect, i.e., patients who did not feel a
benefit from the treatment are likely not to use the device.
The THI is a subjective assessment tool and is one of the most
widely reported outcome measures in tinnitus research. The lack of
a minimum THI score in the inclusion criteria for this study resulted
in a large standard deviation of scores and a large proportion of
included patients who had low baseline values. While this is repre-
sentative of the heterogeneous tinnitus population, patients with
higher baseline THI scores largely drive the improvement in THI
scores observed in this study. In the compliant group, the average
improvement for patients with THI scores of 30 or less (n5 17) was
6 pts (SD5 5 pts). The average improvement for patients with THI
scores greater than 30 was 17 pts (SD5 15 pts). Many studies now
employ minimum scores on tinnitus questionnaires as inclusion cri-
teria (41,43,44). The findings of this study support the use of a mini-
mum threshold of THI as inclusion criteria.
Determining reliable baseline values is essential when meas-
uring clinical effect of any intervention. Our analysis shows that
ascertaining baseline values for tinnitus symptoms is challenging.
The results of this study show that the anticipation of treatment
can contribute to improvements in outcome measures. The clini-
cally significant improvements observed in the run-in phase were
not continued into the treatment phase for the noncompliant
group. During the run-in phase the intra subject variability of THI
was higher (COV 21%) than that of the more objective measures
of TLM and MML (COV 16% and 13% respectively). Our findings
support the use of a run-in phase in tinnitus studies to address
the anticipatory effect and determine reliable baseline values.
Researchers should consider including an appropriate run-in phase
when designing clinical trial protocols for tinnitus treatment evalu-
ation. The tinnitus research community is addressing the lack of
consistency across clinical trials, such as patient assessment and
outcome measures (45). The study reported here has highlighted
the need for guidelines on establishing valid baselines for tinnitus
outcome measures and recommendations for the minimum
threshold of tinnitus severity for inclusion in trials.
The present study demonstrates the feasibly of this device and
provides evidence of improvements in tinnitus symptoms. The
results of this study support the continued evaluation of this inter-
vention as a treatment for tinnitus. The next step is a series of clinical
trials to disassociate the specific and unspecific effects of this thera-
peutic intervention. Parameter optimization studies will investigate
the association of the bi-modal stimuli to determine the optimal
stimulation settings. These studies will be followed by a Randomised
Control Trial to compare this intervention to a sham treatment.
Finally follow-up assessments will be included in all subsequent
studies to examine the permanency of the effect observed in treat-
ment groups.
Table 3. Average Tinnitus Symptom Scores for Baseline and Final Visit.
THI (pts) TLM (dB) MML (dB)
V2 (SD) V7 (SD) V2 (SD) V7 (SD) V2 (SD) V7 (SD)
Full Cohort (41) 33.7 (24) 25.1 (20)*** 42.9 (15) 37.5 (17) 47.3 (15) 39.2 (17)***
Compliant (30) 35.8 (25) 24.1 (20)*** 44.8 (16) 37.3 (16)*** 49.0 (15) 39.2 (18)***
Noncompliant (14) 29.3 (24) 27.4 (23) 38.6 (14) 37.7 (19) 43.8 (17) 39.1 (18)
*p< 0.05, **p< 0.01, ***p< 0.001.
Table 4. Number of Improvers/Nonimprovers for Each Tinnitus Symptom
in Each Compliance Group.
Improvers:
THI*
Improvers:
MML†
Full Cohort (41) 20 (45%) 28 (64%)
Compliant (30) 17 (57%) 22 (73%)
Noncompliant (14) 3 (21%) 6 (43%)
*Improvers achieve a minimum drop of 7 points on THI scale.
†Improvers achieve a minimum drop of 5.3 dB on MML scale.
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COMMENT
This is an interesting pilot study about a new treatment strategy
for tinnitus that combines two different types of stimulation, which
are well established as suitable for tinnitus treatment. I hope to see
a randomized placebo controlled study soon.
Ricardo Figueiredo, MD, MSc
Rio de Janiero, Brazil
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